Search This Blog

Wednesday, January 18, 2023

Tesla, shareholders to lay out arguments in 'funding secured' fraud trial

 

Attorneys for Tesla Inc and for investors will make opening arguments in a San Francisco court on Wednesday in a case to decide whether CEO Elon Musk's 2018 tweet that funding was "secured" to take the company private damaged shareholders.

The case is a rare securities class action trial, and Musk and his company are bucking the norm of settling claims that clear high legal hurdles, making for a potentially dramatic trial at which Musk himself may testify.

Tesla investor Glen Littleton is seeking "billions" in damages on behalf of shareholders who traded the company's stock in the days after Musk posted his plan to take the company private on Twitter in August 2018.

A jury of nine will decide whether the tweets artificially inflated Tesla's share price by playing up the status of funding for the deal, and if so, by how much.

The defendants, who also include current and former Tesla directors, have said they will argue that the stock price jumped in response to Musk saying he was considering taking the company private, which they say was the case, not his assertion about funding.

U.S. District Judge Edward Chen, who is overseeing the trial, has ruled that Musk's statements about the status of the deal were false and Musk made them recklessly. The deal did not happen.

While shareholders sue hundreds of companies and their executives for alleged securities fraud every year, very few of those cases make it to trial. The vast majority are either dismissed by courts or settle.

Not among the jurors selected on Tuesday were some critics of Musk, such as one potential juror who said the chief executive, who has gained a reputation for the unpredictable, was "a little off his rocker."

After opening statements, shareholders will be able to start calling witnesses to the stand. Musk may take the stand in the case, according to court documents, along with former board member Larry Ellison, Oracle Corp co-founder, and current board member James Murdoch, son of Fox Corp Chairman Rupert Murdoch.

https://www.marketscreener.com/news/latest/Tesla-shareholders-to-lay-out-arguments-in-funding-secured-fraud-trial--42757712/

Davos 2023: Moderna CEO in talks with China to supply COVID vaccines

 Moderna chief executive Stephane Bancel said on Wednesday the U.S. company was in active discussions to supply COVID-19 vaccines to China.

Speaking to Reuters on the sidelines of the World Economic Forum annual meeting in Davos, he said the talks with Beijing also covered the topic of factories, and other products including cancer treatments.

"What I really want to understand is how do we help the Chinese government as to what are the needs they have from a healthcare standpoint," he said.

He gave no further details, but said he hoped to visit China this year.

Beijing has so far insisted on using only Chinese-made COVID-19 vaccines for its own population, but the country is beset by a raging COVID outbreak following a U-turn from Beijing on previously ultra-tight anti-pandemic curbs.

Health experts fear the outbreak could intensify in areas less well equipped to handle it, as

millions of Chinese

living in cities head to their hometowns this week for the Lunar New Year holidays.

China-made COVID vaccines are of the inactivated virus type and not based on the messenger RNA technology used in the most widely used shots developed by Moderna and Pfizer -BioNTech.

The only foreign shots being used in China are

BioNTech doses

shipped by Germany late last year and being given to its citizens living there.

The go-ahead to allow expatriate Germans to get a BioNTech shot came as cases surge since Beijing dismantled the zero-COVID lockdown regime.

As regards cancer treatments, Moderna has been working with Merck on an experimental vaccine against melanoma based on the mRNA technology used in successful COVID-19 vaccines. The company has said it plans to study the approach it has used in lung and other highly mutated cancers.

Earlier, in a WEF panel discussion, Bancel said he would like to have factories making vaccines based on its messenger RNA technology on every continent as the U.S. company prepares to build four facilities.

The company, whose COVID-19 vaccines are made in the United States and Switzerland, is building or planning to build plants in Canada, Australia, Britain and Kenya, he said. 

https://www.marketscreener.com/quote/stock/MODERNA-INC-47437573/news/Davos-2023-Moderna-CEO-in-talks-with-China-to-supply-COVID-vaccines-42757614/

Myriad upped to Outperform from Market Perform by Raymond James

 Target $25

https://finviz.com/quote.ashx?t=MYGN&ty=c&ta=1&p=d

Natera upped to Outperform from Market Perform by Raymond James

 Target $58

https://finviz.com/quote.ashx?t=NTRA&p=d

BriaCell: Positive End of Phase II Meeting for Breast Cancer Trial

 

  • BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic breast cancer.

  • After reviewing BriaCell’s Fast Track designated Phase I/IIa data, the FDA has agreed on the primary end point, the essential elements of the pivotal registration study design, and type of patients to be included.

  • Registration study success could lead to a Biologics License Application (BLA) submission and commercialization approvals for BriaCell’s novel immunotherapy approach.

Horizon: Phase 2 Sjögren’s Syndrome Candidate Meets Primary Endpoint

 Trial also met primary endpoint in first study population as announced September 2022 –

The Company plans to work with the FDA to design a Phase 3 program to begin in 2023, ahead of expectations -

https://finance.yahoo.com/news/horizon-therapeutics-plc-announces-phase-130000899.html

NAMUH, Ginkgo to Partner to Produce Multiple Infant Nutrition Products

 NAMUH, an infant nutrition company, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a multi-product collaboration to develop functional oligosaccharides that are structurally identical to those found in human breast milk.

NAMUH's mission is to create complete infant formula products substantially comparable to human breast milk, down to the molecular level. Human Milk Oligosaccharides (HMOs) are essential fiber-like nutrients unique to human milk that provide an important energy source to beneficial gut bacteria in infants. Despite being the third most abundant component in human milk, HMOs are currently a small component in infant formulas, if present at all.

Currently, NAMUH's proprietary technology provides for a cost-effective source of a family of HMOs via yeast fermentation. Through this partnership, NAMUH will leverage Ginkgo's expertise in yeast strain engineering and fermentation process development to enable the production of various HMOs through yeast fermentation and work to unlock the possibility of making infant formula nutritionally robust and much closer to human breast milk.

https://finance.yahoo.com/news/namuh-ginkgo-bioworks-announce-partnership-120000735.html